SCHEMBL10176124

SCHEMBL10176124

O=C1N/C(=N/c2ccccc2)S/C1=C\c1cnc(NCC(F)(F)F)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
MAPT P10636 5/20 0.49
GSK3B P49841 2/20 0.49
CDC25A P30304 1/20 0.44
CDC25B P30305 1/20 0.44
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
CNR1 P21554 1/20 0.43
LMNA P02545 1/20 0.43
DYRK1A Q13627 3/20 0.42
PIM1 P11309 2/20 0.42
PIM3 Q86V86 2/20 0.42
CSNK2A1 P68400 2/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649883 0.87 NPC1 (0.55) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL649879 0.87 NPC1 (0.55) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL652638 0.83 NPC1 (0.51) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL652639 0.83 NPC1 (0.51) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL10176233 0.83 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL651556 0.82 MAPT (0.53) NPC1POLBSMN1; SMN2TDP1MEN1
SCHEMBL651555 0.82 MAPT (0.53) NPC1POLBSMN1; SMN2TDP1MEN1
SCHEMBL651432 0.81 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL651433 0.81 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL650138 0.81 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 NPC1 1074/4885RAB9A 3157/4885POLB 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.